Invivyd, Inc.
IVVD · XNASCIK 1832038fmd_06BXZ7TYGNFQ3W1MEQXRXGPVA9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Apr 01, 2020 to Jun 30, 2026, 24 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total revenues | – | – | 0 | 25 | 53 |
| Realized investment gains (losses) | – | – | 0 | 0 | – |
| Research and development | 183 | 179 | 159 | 137 | 38 |
| Selling, general and administrative | 37 | 47 | 49 | 63 | 67 |
| Total operating expenses | 227 | 248 | 213 | 202 | 109 |
| Operating income | (227) | (248) | (213) | (177) | (56) |
| Other non-operating income (expense) | 0 | 7 | 14 | 7 | 3 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 |
| Net income | (227) | (241) | (199) | (170) | (52) |